Progyny (NASDAQ:PGNY – Get Rating) updated its FY 2022 earnings guidance on Thursday. The company provided EPS guidance of $0.14-$0.19 for the period, compared to the consensus EPS estimate of $0.09. The company issued revenue guidance of $750.00 million-$775.00 million, compared to the consensus revenue estimate of $756.81 million. Progyny also updated its FY22 guidance to $0.14-$0.19 EPS.
Progyny Stock Performance
NASDAQ:PGNY traded up $11.38 on Friday, hitting $41.15. 3,469,925 shares of the stock were exchanged, compared to its average volume of 684,594. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. Progyny has a 52 week low of $25.67 and a 52 week high of $68.32. The company’s 50-day moving average price is $30.23 and its 200 day moving average price is $37.32.
Progyny (NASDAQ:PGNY – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.04. The firm had revenue of $195.00 million during the quarter, compared to analysts’ expectations of $190.51 million. Progyny had a return on equity of 18.11% and a net margin of 7.39%. The company’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 EPS. As a group, equities research analysts predict that Progyny will post 0.17 earnings per share for the current year.
Institutional Trading of Progyny
Large investors have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new stake in Progyny during the 1st quarter worth approximately $62,000. Parkside Financial Bank & Trust bought a new stake in Progyny during the 1st quarter worth approximately $70,000. Captrust Financial Advisors increased its stake in Progyny by 25.0% during the 1st quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after purchasing an additional 418 shares in the last quarter. Mackenzie Financial Corp bought a new stake in Progyny during the 1st quarter worth approximately $216,000. Finally, Bank of Montreal Can increased its stake in Progyny by 25.2% during the 1st quarter. Bank of Montreal Can now owns 7,278 shares of the company’s stock worth $381,000 after purchasing an additional 1,465 shares in the last quarter. 82.51% of the stock is owned by institutional investors.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.